Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

ProACT Post-Approval Study

Uromedica · NCT03767595

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 50+ · Men only
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
145
US sites recruiting
14
Study start
February 19, 2019
Record last updated
October 6, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.

Being studied: ProACT Adjustable Continence Therapy for Men

Conditions: Stress Urinary Incontinence

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Subject is a male of at least 50 years of age.
  • Subject demonstrates stress urinary incontinence.
  • Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery.
  • Subject is willing and able to undergo surgical implantation of ProACT devices.
  • Subject is willing and able to comply with study-required

follow-up activities, including annual telephonic follow -up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies.

  • Subject is willing and able to sign the approved informed consent.
  • Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests).
  • Subject has a negative urine culture.
  • Subject has no known urogenital malignancy, other than previously treated prostate cancer.
  • Subject meets ONE of the following criteria:
  • Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL;
  • Baseline PSA > 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA;
  • Physician determines subject to be a suitable surgical candidate.

Exclusion Criteria

  • Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy.
  • Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months.
  • Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo.
  • Subject has undergone radiation therapy in the prostatic area within the last 12 months.
  • Subject has untreated or unsuccessfully treated detrusor instability or over-activity.
  • Subject has an atonic bladder.
  • Subject had, presently has, or is suspected of having bladder cancer.
  • Subject has untreated or unsuccessfully treated bladder stones.
  • Subject has detrusor sphincter dyssynergia.
  • Subject has known hemophilia or a bleeding disorder.
  • Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest).
  • Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.

Recruiting US locations

  • University of Southern California

    Los Angeles, CA 90033

    Site contact: Julissa Morales · julissa.morales@med.usc.edu

  • Sutter Health

    Santa Barbara, CA 93110

    Site contact: Morgan Caldwell-Holden · morgan.caldwell-holden@sutterhealth.org

  • University of Colorado

    Denver, CO 80045

    Site contact: Andrea Pina · andrea.pinalimones@cuanschutz.edu

  • University of Florida

    Gainesville, FL 32610

    Site contact: John Marks, DHSc, CCRP · 352-273-5618 · John.Marks@urology.ufl.edu

  • Urological Research Network Corp

    Hialeah, FL 33016

    Site contact: Isabel Lopez · isabel@besturology.net

  • Emory University

    Atlanta, GA 30322

    Site contact: Nahir Imtiaz · sbimtia@emory.edu

  • University of Kansas Medical Center

    Kansas City, KS 66103

    Site contact: Kirk Redger, MD · 913-588-1227 · kredger@kumc.edu

  • University of Michigan

    Ann Arbor, MI 48109

    Site contact: Nailah Henry · hnailah@med.umich.edu

  • CentraCare- St. Cloud

    Saint Cloud, MN 56303

    Site contact: Andrew Windsperger, MD · 320-229-4547 · andrew.windsperger@centracare.com

  • CHI Health Research

    Omaha, NE 68124

    Site contact: Jan Mitchell · jan.mitchell@commonspirit.org

  • Lehigh Valley Health Network

    Allentown, PA 18103

    Site contact: Megan McGonagle, MSN, RN, PCCN · Megan.mcgonagle@jefferson.edu

  • Allegheny Health Network

    Pittsburgh, PA 15212

    Site contact: Rachel Reading · rachel.reading@ahn.org

  • Urology Partners of North Texas Research Institute

    Arlington, TX 76017

    Site contact: Grace Yoon · gyoon@folioclinicalresearch.com

  • DHR Health Institute for Research and Development

    McAllen, TX 78504

    Site contact: Clarisa Medina · c.medina@dhrhealth.com

Study contacts (from the official record)

  • Matt Kelly, PhD · 6124698882 · usmtk@coloplast.com
  • Lisa DRAPER · usldr@coloplast.com